Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 148 No. 3738 (2018)

Quality and cost considerations in hyponatraemic patients needing hospitalisation

  • Annina E. Althaus
  • Reto Krapf
DOI
https://doi.org/10.4414/smw.2018.14662
Cite this as:
Swiss Med Wkly. 2018;148:w14662
Published
23.09.2018

Summary

BACKGROUND

Hyponatraemia is the most common electrolyte disorder encountered in hospitalised patients and has an impact on outcome and survival. However, the risk factors are not yet sufficiently known.

AIMS OF THE STUDY

This retrospective analysis was conducted with the primary objective to identify the incidence of hyponatraemia in patients, who need hospitalisation from any medical reason, focusing on the quality of treatment and the risk factors for recurrent or prolonged stay due to hyponatraemia. The secondary objectives were the calculation of costs of hyponatraemia caused by hospital stays in the canton of Basel-Landschaft and the additional extrapolation of these costs for the whole country of Switzerland.

METHODS

368 patients with a diagnosis of hyponatraemia admitted to three tertiary care centers in 2011 were included. We analysed the risk factors, causes and manifestations of hyponatraemia and their effects on length of stay and outcome.

RESULTS

Female gender (62%), advanced age (average 75 ± 12 years) and the use of thiazides (r = 0.69, p = 0.03) represented the main risk factors with negative prognostic value concerning hyponatraemia. Hyponatraemia was never asymptomatic. Seventy-three patients (20%) were diagnosed with hyponatraemia due to SIADH (syndrome of inappropriate antidiuretic hormone secretion). The in-hospital mortality rate was 9%, irrespective of the severity of hyponatraemia, and every fifth patient had persistent neurological deficits on discharge from the hospital. Age (r = 0.65, p = 0.03), female sex (r = 0.49, p =0.12; in combination with age >75years r = 0.58, p = 0.049), resumption of risk medication (r = 0.563, p = 0.02) and persistent hyponatraemia on discharge (r = −0.51, p = 0.04) were associated with higher probability of relapse. Our data, extrapolated for Switzerland, yield uncovered annual costs of 93 million CHF, mostly due to in-hospital treatment longer than that reimbursed by SwissDRG (observed median of 9 days, cost coverage by SwissDRG 5 days for non-SIADH hyponatraemia and 6.5 days for SIADH).

CONCLUSIONS

As even mild hyponatraemia is associated with an increased risk of morbidity and mortality, it is highly important to recognise it. Initial diagnostic evaluation, treatment based on volume status and thorough follow-up are crucial to avoid relapse. Hyponatraemia, based on the results of this retrospective study, constitutes a considerable medical and economic burden in Switzerland and has a serious impact on the hospital balance sheets.

References

  1. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342(21):1581–9. doi:.https://doi.org/10.1056/NEJM200005253422107
  2. Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med. 2010;170(3):294–302. doi:.https://doi.org/10.1001/archinternmed.2009.513
  3. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006;119(7, Suppl 1):S30–5. doi:.https://doi.org/10.1016/j.amjmed.2006.05.005
  4. Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta. 2003;337(1-2):169–72. doi:.https://doi.org/10.1016/j.cccn.2003.08.001
  5. Arampatzis S, Frauchiger B, Fiedler GM, Leichtle AB, Buhl D, Schwarz C, et al. Characteristics, symptoms, and outcome of severe dysnatremias present on hospital admission. Am J Med. 2012;125(11):1125.e1–7. doi:.https://doi.org/10.1016/j.amjmed.2012.04.041
  6. Sherlock M, O’Sullivan E, Agha A, Behan LA, Rawluk D, Brennan P, et al. The incidence and pathophysiology of hyponatraemia after subarachnoid haemorrhage. Clin Endocrinol (Oxf). 2006;64(3):250–4. doi:.https://doi.org/10.1111/j.1365-2265.2006.02432.x
  7. Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med. 2005;352(18):1884–90. doi:.https://doi.org/10.1056/NEJMoa042743
  8. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007;356(20):2064–72. doi:.https://doi.org/10.1056/NEJMcp066837
  9. Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med. 1967;42(5):790–806. doi:.https://doi.org/10.1016/0002-9343(67)90096-4
  10. Boscoe A, Paramore C, Verbalis JG. Cost of illness of hyponatremia in the United States. Cost Eff Resour Alloc. 2006;4(1):10. doi:.https://doi.org/10.1186/1478-7547-4-10
  11. Arbeitsgruppe S. Fixed rate per case payments in Swiss hospitals, S. AG, Editor. 2015: Bern, Schweiz.
  12. Arbeitsgruppe S. Liste der Netzwerkspitaeler Akutsomatik, S. AG, Editor. 2018: Bern, Schweiz.
  13. Statistik Bf. Die Bevölkerung der Schweiz 2011, B.f. Statistik, Editor. 2011: Neuchâtel.
  14. Ammann N. Statistik Baselland des Statistischen Amtes Baselland, S.A. Baselland, Editor. 2013, Schul- und Büromaterialverwaltung Baselland.
  15. Statistik Bf. Regionalporträts 2011: Kantone. Statistischer Atlas der Schweiz, B.f. Statistik, Editor. 2013, Bundesamt für Statistik: Neuchâtel.
  16. Kantonsspital Baselland HDSS. Qualitätsbericht 2012, K. Baselland, Editor. 2012.
  17. Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10, Suppl 1):S1–42. doi:.https://doi.org/10.1016/j.amjmed.2013.07.006
  18. Statistik Bf. Kosten der stationären Spitalaufenthalte 2011. B.f. Statistik, Editor, 2011: Neuchâtel.
  19. Nigro N, Winzeler B, Suter-Widmer I, Schuetz P, Arici B, Bally M, et al. Symptoms and characteristics of individuals with profound hyponatremia: a prospective multicenter observational study. J Am Geriatr Soc. 2015;63(3):470–5. doi:.https://doi.org/10.1111/jgs.13325
  20. Adrogué HJ, Madias NE. The challenge of hyponatremia. J Am Soc Nephrol. 2012;23(7):1140–8. doi:.https://doi.org/10.1681/ASN.2012020128
  21. Douglas I. Hyponatremia: why it matters, how it presents, how we can manage it. Cleve Clin J Med. 2006;73(Suppl 3):S4–12. doi:.https://doi.org/10.3949/ccjm.73.Suppl_3.S4
  22. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, et al.; Hyponatraemia Guideline Development Group. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant. 2014;29(Suppl 2):i1–39. doi:.https://doi.org/10.1093/ndt/gfu040
  23. Greenberg A, Verbalis JG, Amin AN, Burst VR, Chiodo JA, 3rd, Chiong JR, et al. Current treatment practice and outcomes. Report of the hyponatremia registry. Kidney Int. 2015;88(1):167–77. doi:.https://doi.org/10.1038/ki.2015.4
  24. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006;119(1):71.e1–8. doi:.https://doi.org/10.1016/j.amjmed.2005.09.026
  25. Hoorn EJ, Rivadeneira F, van Meurs JB, Ziere G, Stricker BH, Hofman A, et al. Mild hyponatremia as a risk factor for fractures: the Rotterdam Study. J Bone Miner Res. 2011;26(8):1822–8. doi:.https://doi.org/10.1002/jbmr.380
  26. Verbalis JG, Barsony J, Sugimura Y, Tian Y, Adams DJ, Carter EA, et al. Hyponatremia-induced osteoporosis. J Bone Miner Res. 2010;25(3):554–63. doi:.https://doi.org/10.1359/jbmr.090827
  27. Ayus JC, Moritz ML. Bone disease as a new complication of hyponatremia: moving beyond brain injury. Clin J Am Soc Nephrol. 2010;5(2):167–8. doi:.https://doi.org/10.2215/CJN.09281209
  28. Kinsella S, Moran S, Sullivan MO, Molloy MG, Eustace JA. Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol. 2010;5(2):275–80. doi:.https://doi.org/10.2215/CJN.06120809
  29. Tamma R, Sun L, Cuscito C, Lu P, Corcelli M, Li J, et al. Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia. Proc Natl Acad Sci USA. 2013;110(46):18644–9. doi:. Corrected in: Proc Natl Acad Sci USA. 2014;111(38):14002. doi:http://dx.doi.org/10.1073/pnas.1415306111 https://doi.org/10.1073/pnas.1318257110
  30. Amin A, Deitelzweig S, Christian R, Friend K, Lin J, Belk K, et al. Evaluation of incremental healthcare resource burden and readmission rates associated with hospitalized hyponatremic patients in the US. J Hosp Med. 2012;7(8):634–9. doi:.https://doi.org/10.1002/jhm.1973
  31. Szucs TD. Gesundheitsökonomische Aspekte der chronischen Herzinsuffizienz. Schweiz Arzteztg. 2003;84(46):2431–41. doi:.https://doi.org/10.4414/saez.2003.10090
  32. Gesundheit SWABf. Kosten der nichtübertragbaren Krankheiten in der Schweiz, Schlussbericht, B.f. Gesundheit, Editor. 2014: Neuchâtel.
  33. Robertson GL. Physiology of ADH secretion. Kidney Int Suppl. 1987;21:S20–6.